ID   AK1C1_HUMAN             Reviewed;         323 AA.
AC   Q04828; P52896; Q5SR15; Q7M4N2; Q9UCX2;
DT   01-OCT-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1993, sequence version 1.
DT   28-JUN-2023, entry version 217.
DE   RecName: Full=Aldo-keto reductase family 1 member C1 {ECO:0000305};
DE            EC=1.1.1.- {ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:11013348, ECO:0000269|PubMed:14672942, ECO:0000269|PubMed:19218247, ECO:0000269|PubMed:8486699, ECO:0000269|PubMed:8573067};
DE            EC=1.1.1.112 {ECO:0000269|PubMed:8573067};
DE            EC=1.1.1.209 {ECO:0000269|PubMed:10998348};
DE            EC=1.1.1.210 {ECO:0000269|PubMed:14672942, ECO:0000269|PubMed:19218247};
DE            EC=1.1.1.357 {ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:11013348};
DE            EC=1.1.1.51 {ECO:0000269|PubMed:10998348};
DE            EC=1.1.1.53 {ECO:0000269|PubMed:10998348};
DE            EC=1.1.1.62 {ECO:0000269|PubMed:10998348};
DE            EC=1.3.1.20 {ECO:0000269|PubMed:8486699, ECO:0000269|PubMed:8573067};
DE   AltName: Full=20-alpha-hydroxysteroid dehydrogenase {ECO:0000303|PubMed:11013348};
DE            Short=20-alpha-HSD {ECO:0000303|PubMed:11013348};
DE            EC=1.1.1.149 {ECO:0000305|PubMed:11013348};
DE   AltName: Full=Chlordecone reductase homolog HAKRC;
DE   AltName: Full=Dihydrodiol dehydrogenase 1 {ECO:0000303|PubMed:8573067};
DE            Short=DD1 {ECO:0000303|PubMed:8573067};
DE   AltName: Full=High-affinity hepatic bile acid-binding protein;
DE            Short=HBAB;
GN   Name=AKR1C1; Synonyms=DDH, DDH1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], CATALYTIC ACTIVITY, PARTIAL PROTEIN SEQUENCE,
RP   AND SUBCELLULAR LOCATION.
RC   TISSUE=Liver;
RX   PubMed=8486699; DOI=10.1016/s0021-9258(18)82220-7;
RA   Stolz A., Hammond L., Lou H., Takikawa H., Ronk M., Shively J.E.;
RT   "cDNA cloning and expression of the human hepatic bile acid-binding
RT   protein. A member of the monomeric reductase gene family.";
RL   J. Biol. Chem. 268:10448-10457(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RX   PubMed=8132567; DOI=10.1016/s0021-9258(17)37210-1;
RA   Lou H., Hammond L., Sharma V., Sparkes R.S., Lusis A.J., Stolz A.;
RT   "Genomic organization and chromosomal localization of a novel human hepatic
RT   dihydrodiol dehydrogenase with high affinity bile acid binding.";
RL   J. Biol. Chem. 269:8416-8422(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Colon;
RX   PubMed=7515059; DOI=10.1016/s0021-9258(17)40716-2;
RA   Ciaccio P.J., Jaiswal A.K., Tew K.D.;
RT   "Regulation of human dihydrodiol dehydrogenase by Michael acceptor
RT   xenobiotics.";
RL   J. Biol. Chem. 269:15558-15562(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=7626489; DOI=10.1016/0960-0760(95)00019-v;
RA   Khanna M., Qin K.-N., Cheng K.-C.;
RT   "Distribution of 3 alpha-hydroxysteroid dehydrogenase in rat brain and
RT   molecular cloning of multiple cDNAs encoding structurally related proteins
RT   in humans.";
RL   J. Steroid Biochem. Mol. Biol. 53:41-46(1995).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Liver;
RX   PubMed=10672042; DOI=10.1046/j.1365-2443.2000.00310.x;
RA   Nishizawa M., Nakajima T., Yasuda K., Kanzaki H., Sasaguri Y., Watanabe K.,
RA   Ito S.;
RT   "Close kinship of human 20alpha-hydroxysteroid dehydrogenase gene with
RT   three aldo-keto reductase genes.";
RL   Genes Cells 5:111-125(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, CATALYTIC ACTIVITY, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Skin fibroblast;
RX   PubMed=11013348; DOI=10.1677/jme.0.0250221;
RA   Zhang Y., Dufort I., Rheault P., Luu-The V.;
RT   "Characterization of a human 20alpha-hydroxysteroid dehydrogenase.";
RL   J. Mol. Endocrinol. 25:221-228(2000).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D.C., Burrill W., Burton J., Cahill P., Camire D., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S., Corby N.,
RA   Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L., Frankish A.,
RA   Frankland J.A., Garner P., Garnett J., Gribble S., Griffiths C.,
RA   Grocock R., Gustafson E., Hammond S., Harley J.L., Hart E., Heath P.D.,
RA   Ho T.P., Hopkins B., Horne J., Howden P.J., Huckle E., Hynds C.,
RA   Johnson C., Johnson D., Kana A., Kay M., Kimberley A.M., Kershaw J.K.,
RA   Kokkinaki M., Laird G.K., Lawlor S., Lee H.M., Leongamornlert D.A.,
RA   Laird G., Lloyd C., Lloyd D.M., Loveland J., Lovell J., McLaren S.,
RA   McLay K.E., McMurray A., Mashreghi-Mohammadi M., Matthews L., Milne S.,
RA   Nickerson T., Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V.,
RA   Peck A.I., Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A.,
RA   Ross M.T., Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W., Tracey A.,
RA   Tromans A., Tsolas J., Wall M., Walsh J., Wang H., Weinstock K., West A.P.,
RA   Willey D.L., Whitehead S.L., Wilming L., Wray P.W., Young L., Chen Y.,
RA   Lovering R.C., Moschonas N.K., Siebert R., Fechtel K., Bentley D.,
RA   Durbin R.M., Hubbard T., Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Lung, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 4-323.
RC   TISSUE=Liver;
RX   PubMed=8274401; DOI=10.1016/0960-0760(93)90308-j;
RA   Qin K.-N., New M.I., Cheng K.-C.;
RT   "Molecular cloning of multiple cDNAs encoding human enzymes structurally
RT   related to 3 alpha-hydroxysteroid dehydrogenase.";
RL   J. Steroid Biochem. Mol. Biol. 46:673-679(1993).
RN   [11]
RP   PROTEIN SEQUENCE OF 10-31; 40-61; 69-126; 137-153; 162-206; 209-230;
RP   250-267; 271-289 AND 295-323, FUNCTION, CATALYTIC ACTIVITY, ACTIVITY
RP   REGULATION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=8573067; DOI=10.1042/bj3130373;
RA   Hara A., Matsuura K., Tamada Y., Sato K., Miyabe Y., Deyashiki Y.,
RA   Ishida N.;
RT   "Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-
RT   acid-binding protein and an oxidoreductase of human colon cells.";
RL   Biochem. J. 313:373-376(1996).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 18-323, AND PROTEIN SEQUENCE OF 18-31;
RP   105-131; 176-193 AND 271-294.
RC   TISSUE=Liver;
RX   PubMed=8172617; DOI=10.1042/bj2990545;
RA   Deyashiki Y., Ogasawara A., Nakayama T., Nakanishi M., Miyabe Y., Sato K.,
RA   Hara A.;
RT   "Molecular cloning of two human liver 3 alpha-hydroxysteroid/dihydrodiol
RT   dehydrogenase isoenzymes that are identical with chlordecone reductase and
RT   bile-acid binder.";
RL   Biochem. J. 299:545-552(1994).
RN   [13]
RP   FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBSTRATE
RP   SPECIFICITY, AND TISSUE SPECIFICITY.
RX   PubMed=10998348; DOI=10.1042/0264-6021:3510067;
RA   Penning T.M., Burczynski M.E., Jez J.M., Hung C.F., Lin H.K., Ma H.,
RA   Moore M., Palackal N., Ratnam K.;
RT   "Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the
RT   aldo-keto reductase superfamily: functional plasticity and tissue
RT   distribution reveals roles in the inactivation and formation of male and
RT   female sex hormones.";
RL   Biochem. J. 351:67-77(2000).
RN   [14]
RP   FUNCTION, CATALYTIC ACTIVITY, PATHWAY, AND ACTIVITY REGULATION.
RX   PubMed=14672942; DOI=10.1074/jbc.m313308200;
RA   Steckelbroeck S., Jin Y., Gopishetty S., Oyesanmi B., Penning T.M.;
RT   "Human cytosolic 3alpha-hydroxysteroid dehydrogenases of the aldo-keto
RT   reductase superfamily display significant 3beta-hydroxysteroid
RT   dehydrogenase activity: implications for steroid hormone metabolism and
RT   action.";
RL   J. Biol. Chem. 279:10784-10795(2004).
RN   [15]
RP   FUNCTION, CATALYTIC ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=19218247; DOI=10.1074/jbc.m809465200;
RA   Jin Y., Duan L., Lee S.H., Kloosterboer H.J., Blair I.A., Penning T.M.;
RT   "Human cytosolic hydroxysteroid dehydrogenases of the aldo-ketoreductase
RT   superfamily catalyze reduction of conjugated steroids: implications for
RT   phase I and phase II steroid hormone metabolism.";
RL   J. Biol. Chem. 284:10013-10022(2009).
RN   [16]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) IN COMPLEX WITH NADP AND
RP   20ALPHA-HYDROXY-PROGESTERONE, AND MUTAGENESIS OF GLU-127; HIS-222; ARG-304;
RP   TYR-305; THR-307 AND ASP-309.
RX   PubMed=12899831; DOI=10.1016/s0022-2836(03)00762-9;
RA   Couture J.-F., Legrand P., Cantin L., Luu-The V., Labrie F., Breton R.;
RT   "Human 20alpha-hydroxysteroid dehydrogenase: crystallographic and site-
RT   directed mutagenesis studies lead to the identification of an alternative
RT   binding site for C21-steroids.";
RL   J. Mol. Biol. 331:593-604(2003).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (1.87 ANGSTROMS) IN COMPLEX WITH NADP AND
RP   3-CHLORO-5-PHENYLSALICYLIC ACID.
RX   PubMed=21414777; DOI=10.1016/j.bmcl.2011.01.076;
RA   El-Kabbani O., Dhagat U., Soda M., Endo S., Matsunaga T., Hara A.;
RT   "Probing the inhibitor selectivity pocket of human 20alpha-hydroxysteroid
RT   dehydrogenase (AKR1C1) with X-ray crystallography and site-directed
RT   mutagenesis.";
RL   Bioorg. Med. Chem. Lett. 21:2564-2567(2011).
CC   -!- FUNCTION: Cytosolic aldo-keto reductase that catalyzes the NADH and
CC       NADPH-dependent reduction of ketosteroids to hydroxysteroids
CC       (PubMed:19218247). Most probably acts as a reductase in vivo since the
CC       oxidase activity measured in vitro is inhibited by physiological
CC       concentrations of NADPH (PubMed:14672942). Displays a broad positional
CC       specificity acting on positions 3, 17 and 20 of steroids and regulates
CC       the metabolism of hormones like estrogens and androgens
CC       (PubMed:10998348). May also reduce conjugated steroids such as 5alpha-
CC       dihydrotestosterone sulfate (PubMed:19218247). Displays affinity for
CC       bile acids (PubMed:8486699). {ECO:0000269|PubMed:10998348,
CC       ECO:0000269|PubMed:14672942, ECO:0000269|PubMed:19218247,
CC       ECO:0000269|PubMed:8486699}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 3alpha-hydroxysteroid + NADP(+) = a 3-oxosteroid + H(+) +
CC         NADPH; Xref=Rhea:RHEA:34783, ChEBI:CHEBI:15378, ChEBI:CHEBI:36835,
CC         ChEBI:CHEBI:47788, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         EC=1.1.1.357; Evidence={ECO:0000269|PubMed:10998348,
CC         ECO:0000269|PubMed:11013348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 3alpha-hydroxysteroid + NAD(+) = a 3-oxosteroid + H(+) +
CC         NADH; Xref=Rhea:RHEA:34779, ChEBI:CHEBI:15378, ChEBI:CHEBI:36835,
CC         ChEBI:CHEBI:47788, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945;
CC         EC=1.1.1.357; Evidence={ECO:0000269|PubMed:10998348,
CC         ECO:0000269|PubMed:11013348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(17R,20S)-17,20-dihydroxypregn-4-en-3-one + NADP(+) = 17alpha-
CC         hydroxyprogesterone + H(+) + NADPH; Xref=Rhea:RHEA:15857,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16418, ChEBI:CHEBI:17252,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; EC=1.1.1.149;
CC         Evidence={ECO:0000305|PubMed:11013348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:15859;
CC         Evidence={ECO:0000305|PubMed:11013348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(17R,20S)-17,20-dihydroxypregn-4-en-3-one + NAD(+) = 17alpha-
CC         hydroxyprogesterone + H(+) + NADH; Xref=Rhea:RHEA:15853,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16418, ChEBI:CHEBI:17252,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; EC=1.1.1.149;
CC         Evidence={ECO:0000305|PubMed:11013348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:15855;
CC         Evidence={ECO:0000305|PubMed:11013348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(20S)-hydroxypregn-4-en-3-one + NADP(+) = H(+) + NADPH +
CC         progesterone; Xref=Rhea:RHEA:42112, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:17026, ChEBI:CHEBI:28453, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349; Evidence={ECO:0000269|PubMed:10998348,
CC         ECO:0000269|PubMed:11013348};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42113;
CC         Evidence={ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:11013348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42114;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(20S)-hydroxypregn-4-en-3-one + NAD(+) = H(+) + NADH +
CC         progesterone; Xref=Rhea:RHEA:42108, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:17026, ChEBI:CHEBI:28453, ChEBI:CHEBI:57540,
CC         ChEBI:CHEBI:57945; Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42109;
CC         Evidence={ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:11013348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42110;
CC         Evidence={ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:11013348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(1R,2R)-1,2-dihydrobenzene-1,2-diol + NADP(+) = catechol +
CC         H(+) + NADPH; Xref=Rhea:RHEA:16729, ChEBI:CHEBI:10702,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:18135, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349; EC=1.3.1.20; Evidence={ECO:0000269|PubMed:8486699,
CC         ECO:0000269|PubMed:8573067};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(S)-indan-1-ol + NAD(+) = H(+) + indan-1-one + NADH;
CC         Xref=Rhea:RHEA:16317, ChEBI:CHEBI:15378, ChEBI:CHEBI:17404,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:57945, ChEBI:CHEBI:156384;
CC         EC=1.1.1.112; Evidence={ECO:0000269|PubMed:8573067};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(S)-indan-1-ol + NADP(+) = H(+) + indan-1-one + NADPH;
CC         Xref=Rhea:RHEA:16321, ChEBI:CHEBI:15378, ChEBI:CHEBI:17404,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, ChEBI:CHEBI:156384;
CC         EC=1.1.1.112; Evidence={ECO:0000269|PubMed:8573067};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5alpha-androstane-3alpha,17beta-diol + NADP(+) = 17beta-
CC         hydroxy-5alpha-androstan-3-one + H(+) + NADPH; Xref=Rhea:RHEA:42116,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16330, ChEBI:CHEBI:36713,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         Evidence={ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:14672942};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42118;
CC         Evidence={ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:14672942};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5alpha-androstane-3beta,17beta-diol + NADP(+) = 17beta-
CC         hydroxy-5alpha-androstan-3-one + H(+) + NADPH; Xref=Rhea:RHEA:16297,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16330, ChEBI:CHEBI:18329,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; EC=1.1.1.210;
CC         Evidence={ECO:0000269|PubMed:14672942, ECO:0000269|PubMed:19218247};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:16299;
CC         Evidence={ECO:0000269|PubMed:14672942, ECO:0000269|PubMed:19218247};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5alpha-androstane-3alpha,17beta-diol + NAD(+) = 17beta-
CC         hydroxy-5alpha-androstan-3-one + H(+) + NADH; Xref=Rhea:RHEA:42004,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:16330, ChEBI:CHEBI:36713,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; EC=1.1.1.53;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42006;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=17beta-hydroxy-5alpha-androstan-3-one + NADP(+) = 5alpha-
CC         androstan-3,17-dione + H(+) + NADPH; Xref=Rhea:RHEA:42120,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:15994, ChEBI:CHEBI:16330,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42122;
CC         Evidence={ECO:0000305|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=androsterone + NADP(+) = 5alpha-androstan-3,17-dione + H(+) +
CC         NADPH; Xref=Rhea:RHEA:20377, ChEBI:CHEBI:15378, ChEBI:CHEBI:15994,
CC         ChEBI:CHEBI:16032, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349;
CC         EC=1.1.1.209; Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:20379;
CC         Evidence={ECO:0000305|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=androsterone + H(+) + NADPH = 5alpha-androstane-3alpha,17beta-
CC         diol + NADP(+); Xref=Rhea:RHEA:42156, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:16032, ChEBI:CHEBI:36713, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349; Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:42157;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42158;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5alpha-androstane-3alpha,17beta-diol + NAD(+) = androsterone +
CC         H(+) + NADH; Xref=Rhea:RHEA:42124, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:16032, ChEBI:CHEBI:36713, ChEBI:CHEBI:57540,
CC         ChEBI:CHEBI:57945; Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42126;
CC         Evidence={ECO:0000305|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=17beta-estradiol + NADP(+) = estrone + H(+) + NADPH;
CC         Xref=Rhea:RHEA:24616, ChEBI:CHEBI:15378, ChEBI:CHEBI:16469,
CC         ChEBI:CHEBI:17263, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; EC=1.1.1.62;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:24617;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:24618;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=17beta-estradiol + NAD(+) = estrone + H(+) + NADH;
CC         Xref=Rhea:RHEA:24612, ChEBI:CHEBI:15378, ChEBI:CHEBI:16469,
CC         ChEBI:CHEBI:17263, ChEBI:CHEBI:57540, ChEBI:CHEBI:57945; EC=1.1.1.62;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:24613;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:24614;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=NADP(+) + testosterone = androst-4-ene-3,17-dione + H(+) +
CC         NADPH; Xref=Rhea:RHEA:14981, ChEBI:CHEBI:15378, ChEBI:CHEBI:16422,
CC         ChEBI:CHEBI:17347, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349; EC=1.1.1.51;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:14983;
CC         Evidence={ECO:0000305|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=20alpha-hydroxy-5beta-pregnan-3-one + NADP(+) = 5beta-pregnan-
CC         3,20-dione + H(+) + NADPH; Xref=Rhea:RHEA:42168, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30154, ChEBI:CHEBI:57783, ChEBI:CHEBI:58349,
CC         ChEBI:CHEBI:78666; Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:42170;
CC         Evidence={ECO:0000305|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3beta-hydroxy-5beta-pregnane-20-one + NADP(+) = 5beta-pregnan-
CC         3,20-dione + H(+) + NADPH; Xref=Rhea:RHEA:22944, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:16229, ChEBI:CHEBI:30154, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349; Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:22946;
CC         Evidence={ECO:0000305|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=3beta-hydroxy-5beta-pregnane-20-one + H(+) + NADPH =
CC         3beta,20alpha-dihydroxy-5beta-pregnane + NADP(+);
CC         Xref=Rhea:RHEA:65496, ChEBI:CHEBI:15378, ChEBI:CHEBI:16229,
CC         ChEBI:CHEBI:57783, ChEBI:CHEBI:58349, ChEBI:CHEBI:156526;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:65497;
CC         Evidence={ECO:0000269|PubMed:10998348};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(3beta,5alpha,17beta)-3-hydroxyandrostan-17-yl sulfate +
CC         NADP(+) = 5alpha-dihydrotestosterone sulfate + H(+) + NADPH;
CC         Xref=Rhea:RHEA:53120, ChEBI:CHEBI:15378, ChEBI:CHEBI:57783,
CC         ChEBI:CHEBI:58349, ChEBI:CHEBI:136982, ChEBI:CHEBI:136983;
CC         Evidence={ECO:0000269|PubMed:19218247};
CC       PhysiologicalDirection=right-to-left; Xref=Rhea:RHEA:53122;
CC         Evidence={ECO:0000269|PubMed:19218247};
CC   -!- ACTIVITY REGULATION: Inhibited by hexestrol with an IC(50) of 9.5 uM,
CC       1,10-phenanthroline with an IC(50) of 55 uM, 1,7-phenanthroline with an
CC       IC(50) of 72 uM, flufenamic acid with an IC(50) of 6.0 uM, indomethacin
CC       with an IC(50) of 140 uM, ibuprofen with an IC(50) of 950 uM,
CC       lithocholic acid with an IC(50) of 25 uM, ursodeoxycholic acid with an
CC       IC(50) of 340 uM and chenodeoxycholic acid with an IC(50) of 570 uM
CC       (PubMed:8573067). The oxidation reaction is inhibited by low micromolar
CC       concentrations of NADPH (PubMed:14672942).
CC       {ECO:0000269|PubMed:14672942, ECO:0000269|PubMed:8573067}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=5 uM for (s)-tetralol {ECO:0000269|PubMed:8573067};
CC         KM=38 uM for (s)-indan-1-ol {ECO:0000269|PubMed:8573067};
CC         KM=580 uM for benzene dihydrodiol
CC         ((1R,2R)-1,2-dihydrobenzene-1,2-diol) {ECO:0000269|PubMed:8573067};
CC         KM=3 uM for 5-beta-pregnane-3-alpha,20-alpha-diol
CC         {ECO:0000269|PubMed:8573067};
CC         KM=3 uM for 5-beta-pregnan-20-alpha-ol-3-one
CC         {ECO:0000269|PubMed:8573067};
CC         KM=12 uM for 4-pregnen-20-alpha-ol-3-one
CC         {ECO:0000269|PubMed:8573067};
CC         KM=133 uM for 9-alpha,11-beta-prostaglandin F(2)
CC         {ECO:0000269|PubMed:8573067};
CC         KM=2 uM for 5-beta-pregnan-3-alpha-ol-20-one
CC         {ECO:0000269|PubMed:8573067};
CC         KM=1 uM for 5-beta-androstane-3,17-dione
CC         {ECO:0000269|PubMed:8573067};
CC         KM=12 uM for prostaglandin D(2) {ECO:0000269|PubMed:8573067};
CC         KM=2.65 uM for progesterone (in the reduction assay)
CC         {ECO:0000269|PubMed:10998348};
CC         KM=16.2 uM for 3beta-hydroxy-5beta-pregnane-20-one (in the reduction
CC         assay) {ECO:0000269|PubMed:10998348};
CC         KM=14.7 uM for (20S)-hydroxypregn-4-en-3-one (in the oxidation assay)
CC         {ECO:0000269|PubMed:10998348};
CC         KM=80.6 uM for 17beta-hydroxy-5alpha-androstan-3-one (in the
CC         reduction assay) {ECO:0000269|PubMed:10998348};
CC         KM=4.2 uM for 17beta-hydroxy-5alpha-androstan-3-one (in the reduction
CC         assay) {ECO:0000269|PubMed:19218247};
CC         KM=31.7 uM for 17beta-hydroxy-5alpha-androstan-3-one (in the
CC         oxidation assay) {ECO:0000269|PubMed:10998348};
CC         KM=6.77 uM for 5alpha-androstan-3,17-dione (in the reduction assay)
CC         {ECO:0000269|PubMed:10998348};
CC         KM=41.7 uM for 3alpha-hydroxy-5alpha-androstan-17-one/androsterone
CC         (in the oxidation assay) {ECO:0000269|PubMed:10998348};
CC         KM=21 uM for 3alpha-hydroxy-5alpha-androstan-17-one/androsterone (in
CC         the reduction assay) {ECO:0000269|PubMed:10998348};
CC         KM=39.8 uM for testosterone (in the oxidation assay)
CC         {ECO:0000269|PubMed:10998348};
CC         KM=19.4 uM for 20alpha-hydroxy-5beta-pregnan-3-one (in the oxidation
CC         assay) {ECO:0000269|PubMed:10998348};
CC         KM=5.2 uM for 5alpha-dihydrotestosterone sulfate (in the reduction
CC         assay) {ECO:0000269|PubMed:19218247};
CC         Vmax=7.85 nmol/min/mg enzyme for the reduction of progesterone
CC         {ECO:0000269|PubMed:10998348};
CC         Vmax=29.7 nmol/min/mg enzyme for the reduction of
CC         3beta-hydroxy-5beta-pregnane-20-one {ECO:0000269|PubMed:10998348};
CC         Vmax=31.9 nmol/min/mg enzyme for the oxidation of
CC         (20S)-hydroxypregn-4-en-3-one {ECO:0000269|PubMed:10998348};
CC         Vmax=18 nmol/min/mg enzyme for the reduction of
CC         17beta-hydroxy-5alpha-androstan-3-one {ECO:0000269|PubMed:10998348};
CC         Vmax=0.72 nmol/min/mg enzyme for the oxidation of
CC         17beta-hydroxy-5alpha-androstan-3-one {ECO:0000269|PubMed:10998348};
CC         Vmax=12.8 nmol/min/mg enzyme for the reduction of
CC         5alpha-androstan-3,17-dione {ECO:0000269|PubMed:10998348};
CC         Vmax=1.59 nmol/min/mg enzyme for the oxidation of
CC         3alpha-hydroxy-5alpha-androstan-17-one/androsterone
CC         {ECO:0000269|PubMed:10998348};
CC         Vmax=4.79 nmol/min/mg enzyme for the reduction of
CC         3alpha-hydroxy-5alpha-androstan-17-one/androsterone
CC         {ECO:0000269|PubMed:10998348};
CC         Vmax=1.2 nmol/min/mg enzyme for the oxidation of testosterone
CC         {ECO:0000269|PubMed:10998348};
CC         Vmax=87.5 nmol/min/mg enzyme for the oxidation of
CC         20alpha-hydroxy-5beta-pregnan-3-one {ECO:0000269|PubMed:10998348};
CC         Note=kcat is 0.29 min-1 for the reduction of progesterone
CC         (PubMed:10998348). kcat is 1.1 min-1 for the reduction of
CC         3beta-hydroxy-5beta-pregnane-20-one (PubMed:10998348). kcat is 1.2
CC         min-1 for the oxidation of (20S)-hydroxypregn-4-en-3-one
CC         (PubMed:10998348). kcat is 0.66 min-1 for the reduction of
CC         17beta-hydroxy-5alpha-androstan-3-one (PubMed:10998348). kcat is
CC         0.026 min-1 for the oxidation of
CC         17beta-hydroxy-5alpha-androstan-3-one (PubMed:10998348). kcat is 0.47
CC         min-1 for the reduction of 5alpha-androstan-3,17-dione
CC         (PubMed:10998348). kcat is 0.06 min-1 for the oxidation of
CC         3alpha-hydroxy-5alpha-androstan-17-one/androsterone
CC         (PubMed:10998348). kcat is 0.18 min-1 for the reduction of
CC         3alpha-hydroxy-5alpha-androstan-17-one/androsterone
CC         (PubMed:10998348). kcat is 0.044 min-1 for the oxidation of
CC         testosterone (PubMed:10998348). kcat is 3.23 min-1 for the oxidation
CC         of 20alpha-hydroxy-5beta-pregnan-3-one (PubMed:10998348). kcat is
CC         0.74 min-1 for the reduction of 17beta-hydroxy-5alpha-androstan-3-one
CC         (PubMed:19218247). kcat is 0.75 min-1 for the reduction of
CC         5alpha-dihydrotestosterone sulfate (PubMed:19218247).
CC         {ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:19218247};
CC   -!- PATHWAY: Steroid metabolism. {ECO:0000269|PubMed:14672942}.
CC   -!- SUBUNIT: Monomer. {ECO:0000269|PubMed:12899831,
CC       ECO:0000269|PubMed:21414777}.
CC   -!- INTERACTION:
CC       Q04828; P26045: PTPN3; NbExp=6; IntAct=EBI-2116455, EBI-1047946;
CC       Q04828; Q7Z699: SPRED1; NbExp=3; IntAct=EBI-2116455, EBI-5235340;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol {ECO:0000269|PubMed:8486699}.
CC   -!- TISSUE SPECIFICITY: Expressed in all tissues tested including liver,
CC       prostate, testis, adrenal gland, brain, uterus, mammary gland and
CC       keratinocytes. Highest levels found in liver, mammary gland and brain.
CC       {ECO:0000269|PubMed:10998348, ECO:0000269|PubMed:11013348}.
CC   -!- SIMILARITY: Belongs to the aldo/keto reductase family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M86609; AAB02880.1; -; mRNA.
DR   EMBL; U05861; AAA18115.1; -; Genomic_DNA.
DR   EMBL; U05853; AAA18115.1; JOINED; Genomic_DNA.
DR   EMBL; U05854; AAA18115.1; JOINED; Genomic_DNA.
DR   EMBL; U05855; AAA18115.1; JOINED; Genomic_DNA.
DR   EMBL; U05857; AAA18115.1; JOINED; Genomic_DNA.
DR   EMBL; U05858; AAA18115.1; JOINED; Genomic_DNA.
DR   EMBL; U05859; AAA18115.1; JOINED; Genomic_DNA.
DR   EMBL; U05860; AAA18115.1; JOINED; Genomic_DNA.
DR   EMBL; U05684; AAA16227.1; -; mRNA.
DR   EMBL; AB031083; BAA92883.1; -; mRNA.
DR   EMBL; AB032150; BAA92886.1; -; Genomic_DNA.
DR   EMBL; BT007197; AAP35861.1; -; mRNA.
DR   EMBL; AC091817; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL713867; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC015490; AAH15490.1; -; mRNA.
DR   EMBL; BC020216; AAH20216.1; -; mRNA.
DR   EMBL; BC040210; AAH40210.1; -; mRNA.
DR   EMBL; S68290; AAD14012.1; -; mRNA.
DR   EMBL; D26124; BAA05121.1; -; mRNA.
DR   CCDS; CCDS7061.1; -.
DR   PIR; A53436; A53436.
DR   PIR; I73675; I73675.
DR   PIR; S59619; S59619.
DR   PIR; S61515; S61515.
DR   RefSeq; NP_001344.2; NM_001353.5.
DR   PDB; 1MRQ; X-ray; 1.59 A; A=2-323.
DR   PDB; 3C3U; X-ray; 1.80 A; A=1-323.
DR   PDB; 3GUG; X-ray; 1.90 A; A=1-323.
DR   PDB; 3NTY; X-ray; 1.87 A; A=1-323.
DR   PDB; 4YVP; X-ray; 2.60 A; A/B=1-323.
DR   PDB; 6A7A; X-ray; 2.37 A; A=1-323.
DR   PDB; 6IJX; X-ray; 2.20 A; A=1-323.
DR   PDBsum; 1MRQ; -.
DR   PDBsum; 3C3U; -.
DR   PDBsum; 3GUG; -.
DR   PDBsum; 3NTY; -.
DR   PDBsum; 4YVP; -.
DR   PDBsum; 6A7A; -.
DR   PDBsum; 6IJX; -.
DR   AlphaFoldDB; Q04828; -.
DR   SMR; Q04828; -.
DR   BioGRID; 108012; 22.
DR   IntAct; Q04828; 8.
DR   MINT; Q04828; -.
DR   STRING; 9606.ENSP00000370254; -.
DR   BindingDB; Q04828; -.
DR   ChEMBL; CHEMBL5905; -.
DR   DrugBank; DB04674; 2-HYDROXY-3,5-DIIODOBENZOIC ACID.
DR   DrugBank; DB00945; Acetylsalicylic acid.
DR   DrugBank; DB07768; Epitestosterone.
DR   DrugBank; DB01039; Fenofibrate.
DR   DrugBank; DB07931; Hexestrol.
DR   DrugBank; DB06077; Lumateperone.
DR   DrugBank; DB00959; Methylprednisolone.
DR   DrugBank; DB00461; Nabumetone.
DR   DrugBank; DB00157; NADH.
DR   DrugBank; DB03467; Naringenin.
DR   DrugBank; DB03461; Nicotinamide adenine dinucleotide phosphate.
DR   DrugBank; DB00776; Oxcarbazepine.
DR   DrugBank; DB12612; Ozanimod.
DR   DrugBank; DB00936; Salicylic acid.
DR   DrugCentral; Q04828; -.
DR   SwissLipids; SLP:000000802; -.
DR   GlyGen; Q04828; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q04828; -.
DR   PhosphoSitePlus; Q04828; -.
DR   SwissPalm; Q04828; -.
DR   BioMuta; AKR1C1; -.
DR   DMDM; 416877; -.
DR   EPD; Q04828; -.
DR   jPOST; Q04828; -.
DR   MassIVE; Q04828; -.
DR   MaxQB; Q04828; -.
DR   PaxDb; Q04828; -.
DR   PeptideAtlas; Q04828; -.
DR   ProteomicsDB; 58285; -.
DR   Antibodypedia; 23969; 365 antibodies from 37 providers.
DR   CPTC; Q04828; 2 antibodies.
DR   DNASU; 1645; -.
DR   Ensembl; ENST00000380872.9; ENSP00000370254.4; ENSG00000187134.14.
DR   GeneID; 1645; -.
DR   KEGG; hsa:1645; -.
DR   MANE-Select; ENST00000380872.9; ENSP00000370254.4; NM_001353.6; NP_001344.2.
DR   UCSC; uc001ihq.4; human.
DR   AGR; HGNC:384; -.
DR   CTD; 1645; -.
DR   DisGeNET; 1645; -.
DR   GeneCards; AKR1C1; -.
DR   HGNC; HGNC:384; AKR1C1.
DR   HPA; ENSG00000187134; Tissue enhanced (liver).
DR   MalaCards; AKR1C1; -.
DR   MIM; 600449; gene.
DR   neXtProt; NX_Q04828; -.
DR   OpenTargets; ENSG00000187134; -.
DR   PharmGKB; PA24677; -.
DR   VEuPathDB; HostDB:ENSG00000187134; -.
DR   eggNOG; KOG1577; Eukaryota.
DR   GeneTree; ENSGT00940000163208; -.
DR   InParanoid; Q04828; -.
DR   OMA; HLNPNGN; -.
DR   OrthoDB; 890110at2759; -.
DR   PhylomeDB; Q04828; -.
DR   TreeFam; TF106492; -.
DR   BioCyc; MetaCyc:HS10741-MON; -.
DR   BRENDA; 1.1.1.149; 2681.
DR   BRENDA; 1.1.1.270; 2681.
DR   BRENDA; 1.1.1.357; 2681.
DR   BRENDA; 1.1.1.50; 2681.
DR   BRENDA; 1.3.1.20; 2681.
DR   PathwayCommons; Q04828; -.
DR   Reactome; R-HSA-193368; Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol.
DR   Reactome; R-HSA-193775; Synthesis of bile acids and bile salts via 24-hydroxycholesterol.
DR   Reactome; R-HSA-193807; Synthesis of bile acids and bile salts via 27-hydroxycholesterol.
DR   Reactome; R-HSA-975634; Retinoid metabolism and transport.
DR   Reactome; R-HSA-9757110; Prednisone ADME.
DR   SABIO-RK; Q04828; -.
DR   SignaLink; Q04828; -.
DR   SIGNOR; Q04828; -.
DR   BioGRID-ORCS; 1645; 14 hits in 1065 CRISPR screens.
DR   ChiTaRS; AKR1C1; human.
DR   EvolutionaryTrace; Q04828; -.
DR   GeneWiki; AKR1C1; -.
DR   GenomeRNAi; 1645; -.
DR   Pharos; Q04828; Tchem.
DR   PRO; PR:Q04828; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   RNAct; Q04828; protein.
DR   Bgee; ENSG00000187134; Expressed in islet of Langerhans and 98 other tissues.
DR   ExpressionAtlas; Q04828; baseline and differential.
DR   Genevisible; Q04828; HS.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0047006; F:17-alpha,20-alpha-dihydroxypregn-4-en-3-one dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0044594; F:17-beta-hydroxysteroid dehydrogenase (NAD+) activity; IEA:RHEA.
DR   GO; GO:0033703; F:3beta-hydroxy-5beta-steroid dehydrogenase activity; IEA:RHEA.
DR   GO; GO:0047024; F:5alpha-androstane-3beta,17beta-diol dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004032; F:alditol:NADP+ 1-oxidoreductase activity; IDA:UniProtKB.
DR   GO; GO:0004033; F:aldo-keto reductase (NADP) activity; TAS:UniProtKB.
DR   GO; GO:0047044; F:androstan-3-alpha,17-beta-diol dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0047042; F:androsterone dehydrogenase (B-specific) activity; IDA:UniProtKB.
DR   GO; GO:0047023; F:androsterone dehydrogenase activity; IBA:GO_Central.
DR   GO; GO:0032052; F:bile acid binding; IDA:UniProtKB.
DR   GO; GO:0031406; F:carboxylic acid binding; IDA:UniProtKB.
DR   GO; GO:0035410; F:dihydrotestosterone 17-beta-dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004303; F:estradiol 17-beta-dehydrogenase [NAD(P)] activity; IEA:UniProtKB-EC.
DR   GO; GO:0047718; F:indanol dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0047086; F:ketosteroid monooxygenase activity; IDA:UniProtKB.
DR   GO; GO:0016655; F:oxidoreductase activity, acting on NAD(P)H, quinone or similar compound as acceptor; IDA:UniProtKB.
DR   GO; GO:0018636; F:phenanthrene 9,10-monooxygenase activity; IDA:UniProtKB.
DR   GO; GO:0033764; F:steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor; TAS:Reactome.
DR   GO; GO:0047045; F:testosterone 17-beta-dehydrogenase (NADP+) activity; IEA:RHEA.
DR   GO; GO:0030283; F:testosterone dehydrogenase [NAD(P)] activity; IEA:UniProtKB-EC.
DR   GO; GO:0047115; F:trans-1,2-dihydrobenzene-1,2-diol dehydrogenase activity; IDA:UniProtKB.
DR   GO; GO:0015721; P:bile acid and bile salt transport; TAS:UniProtKB.
DR   GO; GO:0008206; P:bile acid metabolic process; IDA:UniProtKB.
DR   GO; GO:0071395; P:cellular response to jasmonic acid stimulus; IDA:UniProtKB.
DR   GO; GO:0042632; P:cholesterol homeostasis; TAS:UniProtKB.
DR   GO; GO:0044597; P:daunorubicin metabolic process; IMP:UniProtKB.
DR   GO; GO:0007586; P:digestion; IDA:UniProtKB.
DR   GO; GO:0044598; P:doxorubicin metabolic process; IMP:UniProtKB.
DR   GO; GO:0030855; P:epithelial cell differentiation; IDA:UniProtKB.
DR   GO; GO:0030299; P:intestinal cholesterol absorption; TAS:UniProtKB.
DR   GO; GO:2000379; P:positive regulation of reactive oxygen species metabolic process; IDA:UniProtKB.
DR   GO; GO:0042448; P:progesterone metabolic process; IDA:UniProtKB.
DR   GO; GO:0006693; P:prostaglandin metabolic process; IBA:GO_Central.
DR   GO; GO:0046683; P:response to organophosphorus; IEP:UniProtKB.
DR   GO; GO:0042574; P:retinal metabolic process; IDA:UniProtKB.
DR   GO; GO:0001523; P:retinoid metabolic process; TAS:Reactome.
DR   GO; GO:0006805; P:xenobiotic metabolic process; TAS:Reactome.
DR   CDD; cd19108; AKR_AKR1C1-35; 1.
DR   Gene3D; 3.20.20.100; NADP-dependent oxidoreductase domain; 1.
DR   InterPro; IPR020471; AKR.
DR   InterPro; IPR044482; AKR1C.
DR   InterPro; IPR018170; Aldo/ket_reductase_CS.
DR   InterPro; IPR023210; NADP_OxRdtase_dom.
DR   InterPro; IPR036812; NADP_OxRdtase_dom_sf.
DR   PANTHER; PTHR11732:SF153; ALDO-KETO REDUCTASE FAMILY 1 MEMBER C1-RELATED; 1.
DR   PANTHER; PTHR11732; ALDO/KETO REDUCTASE; 1.
DR   Pfam; PF00248; Aldo_ket_red; 1.
DR   PIRSF; PIRSF000097; AKR; 1.
DR   PRINTS; PR00069; ALDKETRDTASE.
DR   SUPFAM; SSF51430; NAD(P)-linked oxidoreductase; 1.
DR   PROSITE; PS00798; ALDOKETO_REDUCTASE_1; 1.
DR   PROSITE; PS00062; ALDOKETO_REDUCTASE_2; 1.
DR   PROSITE; PS00063; ALDOKETO_REDUCTASE_3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cytoplasm; Direct protein sequencing; Lipid metabolism; NADP;
KW   Oxidoreductase; Reference proteome.
FT   CHAIN           1..323
FT                   /note="Aldo-keto reductase family 1 member C1"
FT                   /id="PRO_0000124633"
FT   ACT_SITE        55
FT                   /note="Proton donor"
FT                   /evidence="ECO:0000250"
FT   BINDING         20..24
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:12899831,
FT                   ECO:0000269|PubMed:21414777"
FT   BINDING         24
FT                   /ligand="substrate"
FT   BINDING         50
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:12899831,
FT                   ECO:0000269|PubMed:21414777"
FT   BINDING         117
FT                   /ligand="substrate"
FT                   /evidence="ECO:0000250"
FT   BINDING         166..167
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:12899831,
FT                   ECO:0000269|PubMed:21414777"
FT   BINDING         190
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:12899831,
FT                   ECO:0000269|PubMed:21414777"
FT   BINDING         216..222
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:12899831,
FT                   ECO:0000269|PubMed:21414777"
FT   BINDING         222
FT                   /ligand="substrate"
FT   BINDING         227
FT                   /ligand="substrate"
FT   BINDING         270..280
FT                   /ligand="NADP(+)"
FT                   /ligand_id="ChEBI:CHEBI:58349"
FT                   /evidence="ECO:0000269|PubMed:12899831,
FT                   ECO:0000269|PubMed:21414777"
FT   SITE            54
FT                   /note="Important for substrate specificity"
FT                   /evidence="ECO:0000250"
FT   SITE            84
FT                   /note="Lowers pKa of active site Tyr"
FT                   /evidence="ECO:0000250"
FT   SITE            222
FT                   /note="May be involved in the mediating step between the
FT                   transformation of progesterone and the release of the
FT                   cofactor"
FT   VARIANT         170
FT                   /note="R -> H (in dbSNP:rs139588200)"
FT                   /id="VAR_048214"
FT   VARIANT         172
FT                   /note="Q -> L (in dbSNP:rs760575583)"
FT                   /id="VAR_048215"
FT   MUTAGEN         127
FT                   /note="E->D: 30-fold decrease in k(cat)/K(m) value for
FT                   progesterone reduction; no effect on the K(m) value."
FT                   /evidence="ECO:0000269|PubMed:12899831"
FT   MUTAGEN         222
FT                   /note="H->I: Marked decrease in k(cat)/K(m) value for
FT                   progesterone; 24-fold decrease for progesterone reduction;
FT                   18-fold decrease for 20alpha-OHProg oxidation. 95-fold
FT                   decrease in K(m) value for NADPH."
FT                   /evidence="ECO:0000269|PubMed:12899831"
FT   MUTAGEN         222
FT                   /note="H->S: Marked decrease in k(cat)/K(m) value for
FT                   progesterone; 10-fold decrease for progesterone reduction;
FT                   3-fold decrease for 20alpha-OHProg oxidation. 10-fold
FT                   decrease in K(m) value for NADPH."
FT                   /evidence="ECO:0000269|PubMed:12899831"
FT   MUTAGEN         304
FT                   /note="R->L: 70-fold decrease in progesterone reduction. No
FT                   effect on DHT reduction."
FT                   /evidence="ECO:0000269|PubMed:12899831"
FT   MUTAGEN         305
FT                   /note="Y->F: No effect on progesterone reduction."
FT                   /evidence="ECO:0000269|PubMed:12899831"
FT   MUTAGEN         307
FT                   /note="T->V: No effect on progesterone reduction."
FT                   /evidence="ECO:0000269|PubMed:12899831"
FT   MUTAGEN         309
FT                   /note="D->V: No effect on progesterone reduction."
FT                   /evidence="ECO:0000269|PubMed:12899831"
FT   CONFLICT        3
FT                   /note="S -> A (in Ref. 4; no nucleotide entry)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        95
FT                   /note="V -> D (in Ref. 4; no nucleotide entry and 10;
FT                   AAD14012)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        158
FT                   /note="G -> E (in Ref. 4; no nucleotide entry and 10;
FT                   AAD14012)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        171..172
FT                   /note="RQ -> ST (in Ref. 4; no nucleotide entry and 10;
FT                   AAD14012)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        183..184
FT                   /note="KY -> QV (in Ref. 4; no nucleotide entry and 10;
FT                   AAD14012)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        222
FT                   /note="H -> L (in Ref. 4; no nucleotide entry and 10;
FT                   AAD14012)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        319
FT                   /note="F -> I (in Ref. 4; no nucleotide entry and 10;
FT                   AAD14012)"
FT                   /evidence="ECO:0000305"
FT   STRAND          7..9
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   STRAND          15..22
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   HELIX           33..44
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   STRAND          48..50
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   HELIX           53..55
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   HELIX           58..70
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   HELIX           76..78
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   STRAND          80..85
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   HELIX           87..89
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   HELIX           92..106
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   STRAND          111..116
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   STRAND          124..126
FT                   /evidence="ECO:0007829|PDB:3C3U"
FT   STRAND          133..135
FT                   /evidence="ECO:0007829|PDB:4YVP"
FT   HELIX           144..156
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   STRAND          159..167
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   HELIX           170..177
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   STRAND          187..192
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   STRAND          194..197
FT                   /evidence="ECO:0007829|PDB:3GUG"
FT   HELIX           200..208
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   STRAND          212..217
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   TURN            225..227
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   HELIX           235..237
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   HELIX           239..248
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   HELIX           252..262
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   STRAND          266..270
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   HELIX           274..280
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   HELIX           281..285
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   HELIX           290..297
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   HELIX           309..311
FT                   /evidence="ECO:0007829|PDB:1MRQ"
FT   HELIX           318..320
FT                   /evidence="ECO:0007829|PDB:6IJX"
SQ   SEQUENCE   323 AA;  36788 MW;  9CB215478FBD29D5 CRC64;
     MDSKYQCVKL NDGHFMPVLG FGTYAPAEVP KSKALEATKL AIEAGFRHID SAHLYNNEEQ
     VGLAIRSKIA DGSVKREDIF YTSKLWCNSH RPELVRPALE RSLKNLQLDY VDLYLIHFPV
     SVKPGEEVIP KDENGKILFD TVDLCATWEA VEKCKDAGLA KSIGVSNFNR RQLEMILNKP
     GLKYKPVCNQ VECHPYFNQR KLLDFCKSKD IVLVAYSALG SHREEPWVDP NSPVLLEDPV
     LCALAKKHKR TPALIALRYQ LQRGVVVLAK SYNEQRIRQN VQVFEFQLTS EEMKAIDGLN
     RNVRYLTLDI FAGPPNYPFS DEY
//
